Endocrine Abstracts

The Spanish acromegaly registry (REA) is an online epidemiological database created in 1997 to collect clinical and biochemical data of patients with acromegaly followed in Spain.Aim: To study trends in acromegaly treatment over time in Spain.Methods: REA is an online database in which registered endocrinologists collect data from all acromegalic patients seen at their practices in Spain. In the last year the neuroendocrine group o...

Introduction: Functional GH deficiency has been described in fibromyalgia (FM). The efficacy of GH as add-on treatment has been suggested in small studies, but little is known in larger and homogeneous populations.Design: Patients (120) were enrolled in a multicenter, randomized, placebo-controlled trial for 18 months (NCT00933686). FM impact questionnaire (FIQ) >75 (severe), duration of FM >18 months, and stability of the standard therapy (amitr...

Non-functioning pituitary adenomas (NFPA) are the most common pituitary tumours. They usually come to medical attention because of a mass effect and/or hypopituitarism. Tumour shrinkage during therapy with either dopamine agonists (DA) or somatostatin analogues (SSA) has been previously reported in some cases; however, response of NFPA to medical treatment is still poor and unpredictable. Our aim was to explore the molecular mechanisms underlying this lack of efficacy through ...

Pegvisomant (peg) is an effective treatment for acromegaly.Aim: To investigate the prevalence of escape and the incidence of lipodystrophy with peg treatment.Methods: Multicenter retrospective study. Escape was defined as loss of control in patients previously controlled under a stable dose of peg, without any other treatment change. Lipodystrophy was defined as either hypertrophy or atrophy of subcutaneous tissue in areas of drug ...

Introduction: ACROCOMB, a retrospective Spanish Multicenter study, evaluated the efficacy and safety of lanreotide (LAN) combined with cabergoline (CAB), or pegvisomant in patients with acromegaly.Methods: patients treated with LAN+CAB at 44 Spanish Endocrinology Departments were included.Results: 33% male patients, median age: 50.4 years. Mean time from diagnosis: 5.9±6.9 years. Tumour size at diagnosis: 21.9 mm. 83% of patie...